Browsing Tag
Pluvicto
3 posts
Novartis profit plunges 70% after $1.9bn drug impairment despite stronger core earnings
Novartis reported $14.52 billion in quarterly sales and an 11% increase in core operating profit, but statutory net income declined 70% following a major impairment related to its investigational medicine del-desiran. Strong oncology and immunology sales are helping offset generic competition, while the drug pipeline presents new financial uncertainties.
Novartis wins FDA nod for Pluvicto in hormone-sensitive prostate cancer, nearly doubling its addressable pool
FDA's mHSPC label nod nearly doubles Pluvicto's addressable pool. Novartis' five RLT plants and payer coverage now decide how fast $651M Q2 sales scale.
Novartis gets Pluvicto EC approval for advanced prostate cancer
Novartis has received the approval of the European Commission (EC) for Pluvicto (lutetium (177Lu) vipivotide tetraxetan), a targeted…